Aim: To relate functional outcomes to mutation type and age at evaluation in patients with Rett syndrome (RTT). Method: We identified 96 RTT patients with mutations in the MECP2 (methyl-CpG-binding protein 2) gene. Chart analysis, clinical evaluation, and functional measures were completed.
Rett syndrome (RTT) is a genetic disorder affecting between 1 in 10,000-22,000 females [1] . Early development is apparently normal followed by a period of developmental arrest with deterioration in motor skills, cognition, hand function, and speech [2] . Genetic linkage studies have mapped the location of the disease trait to the Xq28 region of the X chromosome with mutations in three of the four exons of the methyl CpG binding protein 2 (MECP2) gene that are found in 90-95% of individuals with RTT [3, 4] .
The ability to perform detailed genetic analysis has revealed more than 200 mutations in the MECP2 gene with eight common missense and truncating mutations (R106W, R133C, T158M, R168X, R255X, R270X, R294X, and R306C) accounting for a majority of patients with RTT [5] . Small deletions in exon 4, large deletions in exons 3 or 4, and a group of uncommon mutations have also been identified in patients with RTT. Taken together, these specific mutations and 
